It's our mission to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. Our technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
Jeffersonville, IN, United States
Not updated yet!
Our company was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy, headed by Prof. Kris Thielemans (and co-founders Carlo Heirman and Sonja van Meirvenne) in tandem with Prof Bart Neyns from the Brussels University Hospital 'UZ Brussel'.
In 2015, we entered into a partnership with Progress Pharma under the leadership of Dirk Reyn, former CEO of Movetis, who now heads eTheRNA immunotherapies management team. In July of that year, we obtained from the VUB a worldwide exclusive license on the TriMix technology.
In March 2016, we secured EUR 24 million in a Series A investment with a strong international syndicate of investors.
This enables the company to continue the development of mRNA-based immunotherapies for melanoma, triple negative breast cancer and infectious diseases.